Please use this identifier to cite or link to this item:
|Title:||Androgens are differentially associated with ovarian cancer subtypes in the Ovarian Cancer Cohort Consortium|
Poole, Elizabeth M.
Arslan, Alan A.
Helzlsouer, Kathy J.
Buring, Julie E.
Lee, I. Min
Onland-Moret, N. Charlotte
Duell, Eric J.
Travis, Ruth C.
Merritt, Melissa A.
Tworoger, Shelley S.
Fortner, Renée T.
|Publisher:||American Association for Cancer Research|
|Abstract:||Invasive epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. The etiology of EOC remains lusive; however, experimental and epidemiologic data suggest a role for hormone-related exposures in ovarian carcinogenesis and risk factor differences by histologic phenotypes and developmental pathways. Research on prediagnosis androgen concentrations and EOC risk has yielded inconclusive results, and analyses incorporating EOC subtypes are sparse. We conducted a pooled analysis of 7 nested case-control studies in the Ovarian Cancer Cohort Consortium to investigate the association between prediagnosis circulating androgens [testosterone, free testosterone, androstenedione, dehydroepiandrosterone sulfate (DHEAS)], sex hormone binding globulin (SHBG), and EOC risk by tumor characteristics (i.e., histology, grade, and stage). The final study population included 1,331 EOC cases and 3,017 matched con-trols. Multivariable conditional logistic regression was used to assess risk associations in pooled individual data. Testosterone was positively associated with EOC risk (all subtypes combined, ORlog(2)=1.12; 95% confidence interval 1.02-1.24); other endogenous androgens and SHBG were not associated with overall risk. Higher concentrations of testosterone and androstenedione associated with an increased risk in endometrioid andmucinous tumors [e.g., testosterone, endometrioid tumors, ORlog2=1.40 (1.03-1.91)], but not serous or clear cell. An inverse association was observed between androstenedione and high grade serous tumors [ORlog2=0.76 (0.60-0.96)]. Our analyses provide further evidence for a role of hormonerelated pathways in EOC risk, with differences in associations between androgens and histologic subtypes of EOC.|
|Note:||Versió postprint del document publicat a: https://doi.org/10.1158/0008-5472.CAN-16-3322|
|It is part of:||Cancer Research, 2017, vol. 77, num. 14, p. 3951-3960|
|Appears in Collections:||Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.